CGEN

Compugen (CGEN)

Compugen Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:CGEN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/01/08	21:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2025/01/08	21:00	PR Newswire (US)	Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors	NASDAQ:CGEN	Compugen Ltd
2024/11/27	21:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/11/27	21:00	PR Newswire (US)	Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies	NASDAQ:CGEN	Compugen Ltd
2024/11/12	21:00	PR Newswire (US)	Compugen Reports Third Quarter 2024 Results	NASDAQ:CGEN	Compugen Ltd
2024/11/11	21:00	PR Newswire (US)	Compugen to Participate in Stifel 2024 Healthcare Conference	NASDAQ:CGEN	Compugen Ltd
2024/11/05	23:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/11/05	23:00	PR Newswire (US)	Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024	NASDAQ:CGEN	Compugen Ltd
2024/10/29	20:00	PR Newswire (US)	Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024	NASDAQ:CGEN	Compugen Ltd
2024/10/07	20:00	PR Newswire (US)	Compugen to Present New Clinical Data at SITC 2024	NASDAQ:CGEN	Compugen Ltd
2024/09/13	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/09/09	20:00	PR Newswire (US)	Compugen to Present at Single Cell Genomics 2024 Conference	NASDAQ:CGEN	Compugen Ltd
2024/08/29	20:00	PR Newswire (US)	Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference	NASDAQ:CGEN	Compugen Ltd
2024/08/06	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/08/06	20:00	PR Newswire (US)	Compugen Reports Second Quarter 2024 Results	NASDAQ:CGEN	Compugen Ltd
2024/08/05	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/07/29	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/07/29	20:00	PR Newswire (US)	Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors	NASDAQ:CGEN	Compugen Ltd
2024/07/23	20:00	PR Newswire (US)	Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024	NASDAQ:CGEN	Compugen Ltd
2024/06/17	20:00	PR Newswire (US)	Compugen to Present at Upcoming Antibody Industrial Symposium	NASDAQ:CGEN	Compugen Ltd
2024/05/30	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/05/30	20:00	PR Newswire (US)	Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	NASDAQ:CGEN	Compugen Ltd
2024/05/20	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/05/20	20:00	PR Newswire (US)	Compugen Reports First Quarter 2024 Results	NASDAQ:CGEN	Compugen Ltd
2024/05/20	19:59	IH Market News	U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip	NASDAQ:CGEN	Compugen Ltd
2024/05/16	20:00	PR Newswire (US)	Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential	NASDAQ:CGEN	Compugen Ltd
2024/05/15	20:02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
2024/05/15	20:00	PR Newswire (US)	Compugen Appoints David Silberman as Chief Financial Officer	NASDAQ:CGEN	Compugen Ltd
2024/05/06	20:00	PR Newswire (US)	Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024	NASDAQ:CGEN	Compugen Ltd
2024/04/25	20:00	PR Newswire (US)	Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	NASDAQ:CGEN	Compugen Ltd